Renal dopamine receptor function in hypertension

Hypertension

Volumn 32, Issue 2, 1998, Pages 187-197

  Hussain, Tahir ^b   Lokhandwala, Mustafa F ^a  

^a UNIVERSITY OF HOUSTON   (United States)

^b NONE

Author keywords

Dopamine; Hypertension, renal; Kidney; Kidney tubules, proximal; Receptors, dopamine

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ADENYLATE CYCLASE; BROMOCRIPTINE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; DOPEXAMINE; FENOLDOPAM; IBOPAMINE; PHOSPHOLIPASE A2; PHOSPHOLIPASE C; PROTON; QUINPIROLE; SODIUM ION;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; DOPAMINE METABOLISM; ENZYME ACTIVITY; HEART FAILURE; ION EXCHANGE; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE ABSORPTION; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR DENSITY; RECEPTOR GENE; RENOVASCULAR HYPERTENSION; REVIEW; SODIUM EXCRETION;

EID: 0031845971     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.32.2.187     Document Type: Review

References (124)

1. Iimura O, Shimamoto K. Suppressed dopaminergic activity and water-sodium handling in kidneys at the prehypertensive stage of essential hypertension. J Auton Pharmacol. 1990;10(suppl 1):73S-77S.
2. Yoshimura M, Ikegaki I, Nishimura M, Takahashi H. Role of dopaminergic mechanisms in the kidney for the pathogenesis of hypertension. J Auton Pharmacol. 1990;10:67S-72S.
3. Aoki K, Kikuchi K, Yamaji I. Attenuated renal production of dopamine in patients with low renin essential hypertension. Clin Exp Hypertens. 1989;A11:403-409.
4. Kinoshita S, Sidhu A, Felder RA. Defective dopamine-1 receptor adenylate cyclase coupling in the proximal convoluted tubule from the spontaneously hypertensive rat. J Clin Invest. 1989;84:1849-1856.
5. Hussain T, Lokhandwala MF. Renal dopamine-1 receptor coupling with Gs and Gq/11 proteins in spontaneously hypertensive rats. Am J Physiol. 1997;272:F339-F346.
6. Horiuchi A, Albrecht FE, Eisner GM, Jose PA, Felder RA. Renal dopamine receptors and pre- and post-cAMP-mediated Na transport defect in spontaneously hypertensive rats. Am J Physiol. 1992;263: F1105-F1111.
7. 1A dopamine receptor in the pathogenesis of genetic hypertension. J Clin Invest. 1996;97: 2283-2288.
8. Asico LD, Fuchs S, Accili D, Carey RM, Eisner GM, Jose PA. Disruption of the dopamine D3 receptor gene produces renin-dependent hypertension. J Am Soc Nephrol. 1997;8:295A. Abstract.
9. Sibley DR, Monsma FJ Jr. Molecular biology of dopamine receptors. Trends Pharmacol Sci. 1992;13:61-69.
10. Lokhandwala MF, Barrett RJ. Cardiovascular dopamine receptors: physiological, pharmacological and therapeutic implications. J Auton Pharmacol. 1982;3:181-186.
11. Goldberg LI, Kohli JD, Glock D. Conclusive evidence of two subtypes of peripheral dopamine receptors. In: Woodruff GN, Poat JA, Roberts PJ, eds. Dopaminergic Systems and Their Regulation. London, UK: Macmillan; 1986:195-212.
12. Felder CC, McKelvey AM, Gitler MS, Eisner GM, Jose PA. Dopamine receptor subtypes in renal brush border and basolateral membrane. Kidney Int. 1989;36:183-193.
13. Lokhandwala MF, Amenta F. Anatomical distribution and function of dopamine receptors in the kidney. FASEB J. 1991;5:3023-3030.
14. 1A receptor gene in proximal convoluted tubule of rat kidneys. Am J Physiol. 1993;264:F280-F285.
15. 1B receptor mRNAs in opossum kidney and brain. Mol Pharmacol. 1993; 44:918-925.
16. 3) as a target for neuroleptics. Nature. 1990;347:146-151.
17. Willems JL, Buylaert WA, Leferve RA, Bogaert MG. Neuronal dopamine receptors on autonomic ganglia and sympathetic nerves and dopamine receptors in gastrointestinal system. Pharmacol Rev. 1985; 37:165-216.
18. Lokhandwala MF. Cardiovascular and renal effects of dopamine receptor agonists. ISI Atlas of Science: Pharmacology. 1988;2:261-266.
19. Felder RA, Blecher M, Eisner GM, Jose PA. Cortical tubular and glomerular dopamine receptors in the rat kidney. Am J Physiol. 1984; 246:F557-F568.
20. 3H]SCH 23390. Am J Physiol. 1989;257: F414-F423.
21. Missale C, Pizzi M, Memo M, Picotti GB, Carruba MO. Postsynaptic D1 and D2 dopamine receptors are present in rabbit renal and mesenteric arteries. Neurosci Lett. 1985;61:207-211.
22. McDonald RH, Goldberg LI, McNay JL, Tuttle EP. Effect of dopamine in man: augmentation of sodium excretion, glomerular filtration rate and renal plasma flow. J Clin Invest. 1964;43:1116-1124.
23. van Veldhuisen DK, Gribes ARJ, deGraeff PA, Lie KI. Effects of dopaminergic agents on cardiac and renal function in normal man and in patients with congestive heart failure. Int J Cardiol. 1992;37:293-300.
24. Jose PA, Raymond JR, Bates MD, Aperia A, Felder RA, Carey RM. The renal dopamine receptors. J Am Soc Nephrol. 1992;2:1265-1278.
25. Lokhandwala MF, Chen CJ. Peripheral dopamine receptors. In: Niznik HB, ed. Dopamine Receptors and Transporters. New York, NY: Marcel Dekker Inc; 1994:89-102.
26. Hegde SS, Ricci A, Amenta F, Lokhandwala MF. Evidence from functional and autoradiographic studies for the presence of tubular dopamine-1 receptors and their involvement in the renal effects of fenoldopam. J Pharmacol Exp Ther. 1989;251:1237-1245.
27. Ball SG, Oates HS, Lee MR. Urinary dopamine in man and rat: effect of inorganic salts on dopamine excretion. Clin Sci Mol Med. 1978;55: 167-173.
28. Romero-Vacchione E, Vasquez J, Lema G, Guerrero H, Rosa F, Bermudez M. Low urinary dopamine excretion associated to low sodium excretion in normotensive Piaroa Amazonian ethnia compared to urban subjects. Invest Clin. 1995;36:61-71.
29. Chen CJ, Lokhandwala MF. Role of renal dopamine in the natriuretic response to different degrees of volume expansion in rats. Clin Exp Hypertens. 1991;13:1117-1126.
30. Hegde SS, Jadhav AL, Lokhandwala MF. Role of kidney dopamine in the natriuretic response to volume expansion in rats. Hypertension. 1989;13:828-834.
31. Oates NS, Ball SG, Perkins CM, Lee MR. Plasma and urine dopamine in man given sodium chloride in the diet. Clin Sci. 1979;56:261-264.
32. Vyas SJ, Jadhav AL, Eichberg J, Lokhandwala MF. Dopamine receptor-mediated activation of phospholipase C is associated with natriuresis during high salt intake. Am J Physiol. 1992;262:F494-F498.
33. Bertorello A, Hokfelt T, Goldstein M, Aperia A. Proximal tubule Na,K-ATPase activity is inhibited during high salt diet: evidence for DA-mediated effect. Am J Physiol. 1988;254:F795-F801.
34. Goldstein M, Fuxe K, Hokfelt T. Characterization and tissue localization of catecholamine synthesizing enzymes. Pharmacol Rev. 1972;24: 293-308.
35. Baines AD, Chan W. Production of urine free dopamine from DOPA: a micropuncture study. Life Sci. 1980;26:253-259.
36. Zimlichman R, Levinson PP, Kelly G, Stull R, Keiser HR, Goldstein DS. Derivation of urinary dopamine from plasma dopa. Clin Sci. 1988; 75:515-520.
37. Gesek FA, Schoolwerth AC. Hormonal interaction with the proximal Na,H-exchanger. Am J Physiol. 1990; 258: F514-F521.
38. Felder CC, Campbell T, Albrecht F, Jose PA. Dopamine inhibits Na-H exchanger activity in renal BBMV by stimulation of adenylate cyclase. Am J Physiol. 1990;259:F297-F303.
39. Chen CJ, Beach RE, Lokhandwala MF. Dopamine fails to inhibit renal tubular sodium pump in hypertensive rats. Hypertension. 1993;21: 364-372.
40. Chen CJ, Lokhandwala MF. Inhibition of Na,K-ATPase in renal proximal tubule by dopamine involves DA-1 receptor activation. Naunyn Schmiedebergs Arch Pharmacol. 1993;347:289-295.
41. Satoh T, Cohen HT, Katz AI. Different mechanisms of renal Na,K-ATPase regulation by protein kinases in the proximal and distal nephron. Am J Physiol. 1993;265:F399-F405.
42. 1A dopamine receptor stimulation inhibits Na,K-ATPase activity through protein kinase A. Mol Pharmacol. 1993;43:281-285.
43. 2 receptors. Am J Physiol. 1990;259:F924-F928.
44. Hussain T, Abdul-Wahab R, Lokhandwala MF. Bromocriptine stimulates Na,K ATPase in renal proximal tubules via cAMP pathway. Eur J Pharmacol. 1997;321:259-263.
45. - cells. Mol Pharmacol. 1996;46:373-378.
46. Siragey HM, Felder RA, Howell NL, Chevalier RL, Peach MJ, Carey RM. Evidence that dopamine-2 mechanisms control renal function. Am J Physiol. 1990;259:F793-F800.
47. Vlanchoyannis J, Weismuller G, Schoeppe W. Effects of dopamine on kidney function and on the adenylyl cyclase phosphodiesterase system in man. Eur J Clin Invest. 1976;6:131-137.
48. Felder CC, Albrecht FE, Campbell T, Eisner GM, Jose PA. cAMP-independent, G protein-linked inhibition of Na/H-exchange in renal brush border by D1 dopamine agonist. Am J Physiol. 1993;264: F1032-F1037.
49. Aperia A, Fryckstedt J, Svensson L, Hemmings HC Jr, Nairn AC, Greengard P. Phosphorylated Mr 32,000 dopamine- and cAMP regulated phosphoprotein inhibits Na,K-ATPase activity in renal tubule cells. Proc Natl Acad Sci U S A. 1991;88:2798-2801.
50. Felder CC, Jose PA, Axelrod J. The dopamine-1 agonist, SKF 82526, stimulates phospholipase C activity independent of adenylate cyclase. J Pharmacol Exp Ther. 1989;248:171-175.
51. Felder CC, Blecher M, Jose PA. Dopamine-1 mediated stimulation of phospholipase C activity in rat renal cortical membranes. J Biol Chem. 1989;264:8739-8745.
52. Vyas SJ, Eichberg J, Lokhandwala MF. Characterization of receptors involved in dopamine-induced activation of phospholipase C in rat renal cortex. J Pharmacol Exp Ther. 1992;260:134-139.
53. Kansra V, Chen CJ, Lokhandwala MF. Dopamine causes stimulation of protein kinase C in rat renal proximal tubules by activating dopamine D1 receptors. Eur J Pharmacol. 1995;289:391-394.
54. 1-Adrenoceptor subtypes mediating stimulation of Na,K-ATPase activity in rat renal proximal tubules. Eur J Pharmacol. 1995;288:139-147.
55. Bertorello A, Aperia A. Na,K-ATPase is an effector protein for protein kinase C in renal proximal tubule cells. Am J Physiol. 1989;256: F370-F373.
56. Yu PY, Asico LD, Eisner GM, Jose PA. Differential regulation of renal phospholipase C by catecholamines. J Clin Invest. 1995;95:304-308.
57. 1A dopamine receptor regulation of phospholipase C (PLC) isoforms expression. Pediatr Res. 1994;35:377A. Abstract.
58. Bertorello A, Aperia A. Regulation of Na,K-ATPase activity in the kidney proximal tubules: involvement of GTP binding proteins. Am J Physiol. 1989;256:F57-F62.
59. 1-like dopamine receptor that couples to activation of phosphoinositide metabolism in brain. J Neurochem. 1994;62:2045-2048.
60. 1A knockout mice. Mol Pharmacol. 1997;51:6-11.
61. Hussain T, Lokhandwala MF. Altered arachidonic acid metabolism contributes to the failure of dopamine to inhibit Na,K-ATPase in kidney of spontaneously hypertensive rats. Clin Exp Hypertens. 1986;18: 963-974.
62. Nowicki S, Cheng XJ, Ohtomo Y, Aperia A. Regulation of renal Na,K-ATPase (NKA) activity by 20-hydroxyeicosatetraenoic acid (20-HETE) is mediated by protein kinase C. J Am Soc Nephrol. 1995;6:760. Abstract.
63. Antonipillai I, Broess MI, Lang D. Evidence that specific dopamine-1 receptor activation is involved in dopamine-induced renin release. Hypertension. 1989;13:463-468.
64. Chen CJ, Apparsundarum S, Lokhandwala MF. Intrarenally produced angiotensin II opposes the natriuretic effect of the dopamine-1 receptor agonist fenoldopam in rats. J Pharmacol Exp Ther. 1991;256:486-491.
65. Cheng HF, Becker BN, Harris RC. Dopamine decreases expression of type-1 angiotensin II receptors in renal proximal tubules. J Clin Invest. 1996;97:2745-2752.
66. Sheikh-Hamad D, Wang YP, Jo OD, Yanagawa N. Dopamine antagonizes the actions of angiotensin II in renal brush border membrane. Am J Physiol. 1993;264:F737-F743.
67. Hussain T, Abdul-Wahab R, Lokhandwala MF. Dopamine-2 (DA-2) receptor modulates angiotensin II response on renal Na,K-ATPase through heterologous desensitization. J Am Soc Nephrol. 1996;7:1678. Abstract.
68. Shikuma R, Yoshimura M, Kambra S, Yamazaki H, Takashina R, Takahashi H, Takeda K, Ijichi H. Dopaminergic modulation of salt-sensitivity in patients with essential hypertension. Life Sci. 1986;38: 915-921.
69. Iimura O, Shimamoto K, Ura N. Dopaminergic activity and water-sodium handling in the kidneys of essential hypertensive subjects: is renal dopaminergic activity suppressed at the prehypertensive stage? J Cardiovasc Pharmacol. 1990;16:56S-58S.
70. Iimura O. The role of renal dopaminergic activity in the pathophysiology of essential hypertension. Jpn Heart J. 1996;37:815-828.
71. Iimura O, Kikuchi K, Takigami Y, Mito T, Tsuzuki M, Shibata S. Enhanced natriuretic response to dopamine infusion in low renin essential hypertension. N Z Med J. 1983;96:860-863.
72. Schoors DF, Dupont AG. Increased dopamine-induced nephrogenous cAMP formation in hypertension. Am J Hypertens. 1991;4:494-499.
73. Kikuchi K, Miyama A, Nakao T. Hemodynamic and natriuretic response to intravenous infusion of dopamine in patients with essential hypertension. Jpn Circ J. 1982;46:486-493.
74. Andrejak M, Hary L. Enhanced dopamine renal responsiveness in patients with hypertension. Clin Pharmacol Ther. 1986;40:610-614.
75. O'Connell DP, Ragsdale NV, Boyd DG, Felder RA, Carey RM. Differential human tubular responses to dopamine type 1 receptor stimulation are determined by blood pressure status. Hypertension. 1997;29: 115-122.
76. Sanada H, Jose PA, Yu PY, Hazen-Martin D, Carey RM, Bruns D, Felder R. Human hypertensive subjects have a renal proximal tubular defect in dopamine-1 receptor/adenylyl cyclase coupling. J Am Soc Nephrol. 1997;8:307A. Abstract.
77. Kuchel O, Shigetomi S. Defective dopamine generation from dihydroxyphenyl-alanine in stable essential hypertensive patients. Hypertension. 1992;19:634-638.
78. Clark BA, Rosa RM, Epstein FH, Young JB, Landsberg L. Altered dopaminergic responses in hypertension. Hypertension. 1992;19: 589-594.
79. Gill JR, Grossman E, Goldstein DS. High urinary dopa and low urinary dopamine to dopa ratio in salt-sensitive hypertension. Hypertension. 1991;18:614-621.
80. Muldoon MF, Terrell DF, Bunker CH, Manuck SB. Family history studies in hypertension research: review of the literature. Am J Hypertens. 1993;6:76-88.
81. DeWardner HE. The primary role of the kidney and salt intake in the aetiology of essential hypertension. Clin Sci. 1990;79:193-200.
82. DeFeo ML, Jadhav AL, Lokhandwala MF. Dietary sodium intake and urinary dopamine and sodium excretion during the course of blood pressure development in Dahl salt-sensitive and salt-resistant rats. Clin Exp Hypertens. 1987;12:2049-2060.
83. Sakamoto T, Chen C, Lokhandwala MF. Lack of renal dopamine production during acute volume expansion in Dahl salt-sensitive rats. Clin Exp Hypertens. 1994;16:197-206.
84. Felder RA, Kinoshita S, Sidhu A, Ohbu K, Kaskel FJ. A renal dopamine-1 receptor defect in two genetic models of hypertension. Am J Hypertens. 1990;3:96S-99S.
85. Nishi A, Eklof AC, Bertorello A, Aperia A. Dopamine regulation of renal Na,K-ATPase activity is lacking in Dahl salt-sensitive rats. Hypertension. 1993;21:767-771.
86. Ohbu K, Kaskel FJ, Kinoshita S, Felder RA. Dopamine-1 receptors in the proximal convoluted tubule of Dahl rats: defective coupling to adenylate cyclase. Am J Physiol. 1995;268:R231-R235.
87. Stier CT Jr, Itskovitz HD, Chen YH. Urinary dopamine and sodium excretion in spontaneously hypertensive rats. Clin Exp Hypertens. 1993; 15:105-123.
88. Kambra S, Yoshimura M, Takahashi H, Ijichi H. Enhanced synthesis of renal dopamine and impaired natriuresis in spontaneously hypertensive rats. Jpn Heart J. 1987;28:594. Abstract.
89. Felder RA, Seikaly MG, Cody P, Eisner GM, Jose PA. Attenuated renal response to dopaminergic drugs in spontaneously hypertensive rats. Hypertension. 1990;15:560-569.
90. Chen CJ, Lokhandwala MF. An impairment of tubular DA-1 receptor function as a causative factor for diminished natriuresis to volume expansion in spontaneously hypertensive rats. Clin Exp Hypertens. 1992;14:615-628.
91. +-exchanger in spontaneously hypertensive rats. Am J Physiol. 1991; 261:F526-F536.
92. Sidhu A, Vachvamichsanong P, Jose PA, Felder RA. Persistent defective coupling of dopamine-1 receptors to G proteins after solubilization from kidney proximal tubules of hypertensive rats. J Clin Invest. 1992;89:789-793.
93. Kansra V, Chen CJ, Lokhandwala MF. Dopamine fails to stimulate protein kinase C activity in renal proximal tubules of hypertensive rats. Clin Exp Hypertens. 1995;17:837-845.
94. Ohbu K, Felder RA. Nephron specificity of dopamine receptor-adenylyl cyclase defect in spontaneous hypertension. Am J Physiol. 1993;264: F274-F279.
95. Felder RA, Kinoshita S, Ohbu K, Mouradian MM, Sibley DR, Monsma FJ Jr, Minowa T, Minowa MT, Canessa LM, Jose PA. Organ specificity of the dopamine receptor/adenylyl cyclase coupling defect in spontaneously hypertensive rats. Am J Physiol. 1993;264:R726-R732.
96. Chen CC, Vyas SJ, Eichberg J, Lokhandwala MF. Diminished phospholipase-C activation by dopamine in spontaneously hypertensive rats. Hypertension. 1992;19:102-108.
97. Vachvamichsanong P, Kimura K, Sidhu A. Differences in photolabeling of DA1 receptors in renal proximal tubules from normotensive rats and SHR. Am J Physiol. 1995;268:F1009-F1016.
98. Sidhu A, Kassis S, Kebabian J, Fishman PH. Sulfhydryl group(s) in the ligand binding of the D-1 dopamine receptor: specific protection by agonist and antagonist. Biochemistry. 1986;25:6695-6701.
99. 1A dopamine receptors: differential sensitivity of receptors to N-ethylmaleimide in normotensive and hypertensive rats. J Hypertens. 1996;14:615-622.
100. Kinoshita S, Felder RA. Ontogeny of DA1 receptor-adenylate cyclase coupling in proximal convoluted tubules. Am J Physiol. 1990;259: F971-F976.
101. Gurich RW, Beach RE. Abnormal regulation of renal proximal tubule Na,K-ATPase by G proteins in spontaneously hypertensive rats. Am J Physiol. 1994;267:F1069-F1075.
102. Goldberg LI. The role of dopamine receptors in the treatment of congestive heart failure. J Cardiovasc Pharmacol. 1989;14(suppl 5):s19-s27.
103. Smit AJ, Meijer S, Wesseling H, Reitsma WD, Donkeer AJM. Impaired renal hemodynamic but conserved natriuretic response to dopamine in patients with renal disease. Nephron. 1989;52:338-346.
104. Olsen NV, Olsen MH, Bonde J, Kanstrup IL, Plum I, Strangaard S, Leyssac PP. Dopamine natriuresis in salt-repleted, water-loaded humans: a dose response study. Br J Clin Pharmacol. 1997;43:509-520.
105. Francis GS, Wilson BC, Rector TS. Hemodynamic, renal and neurohumoral effects of selective oral DA1 receptor agonist (Fenoldopam) in patients with congestive heart failure. Am Heart J. 1988;116:473-479.
106. Murphy MB, McCoy CE, Weber RR, Fredrickson ED, Douglas FL, Goldberg LI. Augmentation of renal blood flow and sodium excretion in hypertensive patients during blood pressure reduction by intravenous administration of dopamine-1 agonist, fenoldopam. Circulation. 1987;76:1312-1318.
107. Elliot WJ, Weber RR, Nelson KS. Renal and hemodynamic effects of intravenous fenoldopam versus nitroprusside in severe hypertension. Circulation. 1990;81:970-977.
108. Chen CJ, Lokhandwala MF. Potentiation by enalaprilat of fenoldopam-evoked natriuresis is due to blockade of intrarenal production of angiotensin II in rat. Naunyn Schmiedebergs Arch Pharmacol. 1995;352:194-200.
109. Goldberg LI, Bass AS. Relative significance of dopamine receptors, beta adrenoceptors and norepinephrine uptake inhibition in the cardiovascular actions of dopexamine hydrochloride. Am J Cardiol. 1988;62: 37C-40C.
110. Lang RM, Borow KM, Neumann A, Carroll JD, Weinen L, Murphy MB, Ghali J, Rajfer SI. Role of beta2-adrenoceptors in mediating positive inotropic activity in the failing heart and its relation to the hemodynamic actions of dopexamine hydrochloride. Am J Cardiol. 1988;62:46C-52C.
111. Vincent JL. Towards improving vital organ function: assessing the role of dopexamine hydrochloride in intensive care medicine. Clin Int Care. 1991;2(suppl):5-54.
112. Gray PA, Bodeham AR, Park GR. A comparison of dopexamine and dopamine to prevent renal impairment in patients undergoing orthotopic liver transplantation. Anesthesia. 1991;46:438-441.
113. Atallah MM, Saied MMA, El-Diasty TA, Gray PA, Park GR. Renal effect of dopexamine hydrochloride in patients with chronic renal dysfunction. Urol Res. 1992;20:419-424.
114. Rajfer SI, Rossen JD, Douglas FL, Goldberg LI, Karrison J. Effects of long-term therapy with oral ibopamine on resting hemodynamics and exercise capacity in patients with heart failure: relationship to the generation of N-methyldopamine and to plasma norepinephrine levels. Circulation. 1988;73:740-748.
115. Hampton JR, van Veldhuisen DJ, Kleber FX, Cowley AJ, Ardia A, Block P, Cortina A, Cserhalmi L, Follath F, Jensen G, Kayanakis J, Lie KI, Mancia G, Skene MM. Randomized study of effect of ibopamine on survival in patients with advanced severe heart failure. Lancet. 1997; 349:971-977.
116. Niebaver J, Coates AJS. Treating chronic heart failure: time to take stock. Lancet. 1997;349:966-967.
117. Chen CJ, Lokhandwala MF. Dopamine receptor agonists in cardiovascular pharmacotherapy. Indian J Pharmacol. 1992;24:72-81.
118. 2-adrenergic receptor desensitization, delineation and specific inhibitors. J Biol Chem. 1990;265:3202-3211.
119. 2-adrenergic receptor: mutation of Cys341 in the carboxy tail leads to an uncoupled nonpalmitoylated form of the receptor. J Biol Chem. 1989;264:7564-7569.
120. Ng GYK, Mouillac B, George SR, Caron M, Dennis M, Bouvier M, O'Dowd BF. Desensitization, phosphorylation and palmitoylalion of the human dopamine D1 receptor. Eur J Pharmacol. 1994;267:7-19.
121. Nicholas AJ, Koster PF, Brooks DP, Ruffolo RR. Effect of fenoldopam on the acute and subacute nephrotoxicity produced by amphotericin B in dogs. J Pharmacol Exp Ther. 1992;260:269-274.
122. Wang YX, Gellai M, Brooks DP. Dopamine DA1 receptor agonist, fenoldopam, reverses glycine-induced hyperfiltration in rats. Am J Physiol. 1992;262(6 pt 2):F1055-F1060.
123. 2-adrenoceptor agonist. Naunyn Schmiedebergs Arch Pharmacol. 1994;350:277-283.
124. 2-adrenoceptor agonist on cardiac function and splanchnic circulation in a canine model of hemorrhagic shock. Naunyn Schmiedebergs Arch Pharmacol. 1993;347:296-300.